Pulse Biosciences, Inc 8-K Filings

PULSE BIOSCIENCES, INC. (PLSE) reported that it has completed patient enrollment in its PRECISE-BTN clinical study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for treating symptomatic benign thyroid nodules. The study was expanded from an original 50-patient design to 100 patients across three U.S. clinical sites.

All 100 patients were enrolled in approximately 12 months at Sarasota Memorial Health Care System, NYU Langone Health, and Weill Cornell Medicine. The first patient has completed the final 12-month follow-up visit. Patients are followed at 1, 3, 6, and 12 months, with endpoints including safety, nodule volume reduction, symptom relief, hormone normalization, and quality-of-life improvements.

Pulse Biosciences, Inc. entered into an equity distribution agreement with Mizuho Securities USA LLC as sales agent, under which the company may, from time to time, offer and sell shares of its common stock having an aggregate offering price of up to $75,000,000.

Sales may be made as “at the market” offerings under Rule 415 through ordinary brokers’ transactions on The Nasdaq Capital Market, to or through market makers, block trades, or other permitted negotiated methods, at market, related, or negotiated prices. The company will pay Mizuho a commission of up to 3.0% of the gross sales price of shares sold, reimburse specified expenses, is not obligated to sell any shares, and may suspend solicitations. The shares are registered on Form S-3 (File No. 333-293596), declared effective February 27, 2026, with a prospectus supplement filed August 6, 2026.

Pulse Biosciences, Inc. reported second quarter 2026 results and clinical updates. Total revenue for the three months ended June 30, 2026 was $0.4 million from product sales during a controlled commercial launch focused on market development and increased procedural utilization. GAAP costs and expenses were $25.7 million, and GAAP net loss was $24.7 million; non-GAAP costs and expenses were $20.5 million with non-GAAP net loss of $19.4 million, primarily reflecting higher clinical program and compensation spending.

The company highlighted rapid, efficient procedures in its endocardial catheter atrial fibrillation program and continued progress toward a CE Mark submission in the second half of 2026, with potential approval anticipated by the middle of 2027. Enrollment in the U.S. pivotal NANOPULSE-AF study has passed the halfway point, even after a 19-patient increase in the enrollment target, and completion is still anticipated by early Q4 2026. Pulse Biosciences announced a partnership with the Clayman Thyroid Center to evaluate its Vybrance system for benign thyroid nodules. Cash and cash equivalents totaled $101.6 million as of June 30, 2026, after raising $46.8 million in net proceeds under an at-the-market program during the quarter and an additional $10.7 million afterward, and the company established a new $75 million ATM facility alongside an effective shelf registration for up to $125 million.

Pulse Biosciences announced that the NANOPULSE-AF pivotal IDE clinical study of its nPulse Cardiac Catheter System for treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation has surpassed its enrollment midpoint. The prospective, multicenter investigation began in April 2026 and is expected to enroll patients at up to 30 sites, including locations outside the United States.

The company’s nano-PFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue and initiating regulated cell death. Management plans to provide additional commentary on study progress during an earnings conference call on August 6 at 1:30pm PT / 4:30pm ET, available via phone and webcast.

Pulse Biosciences, Inc. reported the results of its 2026 Annual Meeting of Stockholders, held virtually via live audio webcast on June 11, 2026. Stockholders voted on director elections and auditor ratification.

All seven director nominees, including Robert W. Duggan, Paul A. LaViolette, Maria Sainz, Manmeet S. Soni, Darrin R. Uecker, Richard A. van den Broek, and Mahkam Zanganeh, D.D.S., were elected to serve until the 2027 Annual Meeting and until their successors are duly elected and qualified. Support levels were high, with each nominee receiving more than 33.5 million votes “For” and relatively few votes “Against” or “Abstained,” alongside 10,974,550 broker non-votes.

Stockholders also ratified the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 45,976,355 votes “For,” 8,265 “Against,” and 17,074 “Abstained.” This confirms both the company’s board composition for the coming year and its choice of external auditor.

Pulse Biosciences plans to redeem its remaining common stock “200% Warrants” issued in the July 3, 2024 rights offering. Holders may exercise these warrants at $11.00 per share until 5:00 p.m. Eastern on July 13, 2026, after which any unexercised warrants will be redeemed for $0.01 per warrant share and then become void.

The company’s right to redeem was triggered because its common stock’s volume weighted average price exceeded $22.00 for 20 consecutive trading days, with an average VWAP of $25.17 over that period. Pulse Biosciences reports it has already raised $60 million in gross proceeds from the rights offering and a further $63.7 million from warrant exercises, and it may receive an additional $2.1 million if all remaining 200% Warrants are exercised before the redemption deadline.

Pulse Biosciences, Inc. reports that its Board of Directors has approved resolutions allowing TD Securities (USA) LLC, as sales agent under an existing Equity Distribution Agreement, to sell common stock to one or more company affiliates at the then current market trading price without a discount.

The Equity Distribution Agreement, dated February 19, 2026, permits at-the-market offerings of common stock with an aggregate offering price of up to $59,976,196. The company notes that Co-Chairman and major stockholder Robert Duggan, who beneficially owned approximately 72% of outstanding common stock as of March 31, 2026, and Chief Executive Officer and Co-Chairman Paul LaViolette have indicated they are likely to purchase shares in the near term, but without any binding commitments or specified amounts.

Pulse Biosciences reported first quarter 2026 results and clinical trial updates. For the three months ended March 31, 2026, revenue was $0.4 million and GAAP net loss was $18.6 million, compared to a net loss of $16.8 million a year earlier, as spending on clinical programs increased.

Total GAAP costs and expenses were $19.6 million, with research and development of $12.6 million and selling, general and administrative expenses of $6.6 million. Non-GAAP costs and expenses were $17.4 million and non-GAAP net loss was $16.4 million.

Cash and cash equivalents were $68.3 million as of March 31, 2026, with $14.6 million used in operating activities during the quarter. The company highlighted accelerated enrollment for its NANOPULSE-AF pivotal trial, now targeting completion in early Q4 2026, and plans to complete NANOCLAMP-AF enrollment by the end of the first half of 2027.

Pulse Biosciences, Inc. furnished an update on its first-in-human clinical study of the nPulse Cardiac Catheter System for atrial fibrillation, highlighting sustained procedure success and efficiency metrics from a multicenter feasibility study in Europe.

At Heart Rhythm 2026, investigators reported 100% procedural success at 6 months in 95 evaluable patients and 96% procedural success at one year in 51 evaluable patients, with a 90% Kaplan-Meier estimate of freedom from AF/AFL/AT at one year. Among 177 treated patients, serious adverse events related to the primary safety endpoint occurred in 1.7% of subjects. The company also posted an updated investor presentation and a detailed press release with these results.

Pulse Biosciences, Inc. furnished an updated investor presentation on its website, highlighting progress and plans across its cardiac and soft tissue programs. The deck adds new details on the pivotal clinical study of its nsPFA Cardiac Catheter for treating atrial fibrillation, describes the next-generation nPulse cardiac catheter under development, and outlines 2026 corporate goals in electrophysiology, cardiac surgery and soft tissue ablation. The company may use this presentation in meetings with investors and analysts. The investor deck is provided as an exhibit and is treated as furnished, not filed, under securities laws, and includes forward-looking statements subject to risks and uncertainties.

Pulse Biosciences, Inc. appointed Liane R. Teplitsky as Chief Operating Officer effective April 8, 2026, and expanded Dr. David Kenigsberg’s role as full-time Chief Medical Officer to support development of its nPulse cardiac catheter ablation system.

Ms. Teplitsky’s at-will Employment Agreement provides a $525,000 annual base salary and a target bonus equal to 70% of base salary, plus eligibility for standard executive benefits. She received a nonstatutory stock option to purchase 700,000 shares at $19.06 per share and 200,000 performance-based restricted stock units under the 2017 Inducement Equity Incentive Plan, with time-based and performance-based vesting tied to market capitalization and revenue milestones.

Pulse also granted inducement options covering 7,700 shares to two other new employees, each with a $19.06 exercise price and four-year time-based vesting.

Pulse Biosciences reported that it has enrolled and treated the first seven patients in its NANOPULSE-AF IDE pivotal clinical study of the nPulse™ Cardiac Catheter System for recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation. The prospective, multicenter investigation plans to enroll about 215 participants across multiple sites in the United States and Europe.

Primary endpoints will be assessed at 6 and 12 months post-ablation to evaluate procedural success and safety. The study builds on a first-in-human feasibility trial that showed 96% procedural success at 12 months and 100% acute success, in a setting where atrial fibrillation recurrence of 20–25% is described as typical. The system uses nanosecond pulsed field ablation energy and is integrated with Abbott’s EnSite X 3D electroanatomical mapping software.

Pulse Biosciences, Inc. reported that its Compensation Committee granted Chief Technology Officer Darrin R. Uecker a restricted stock unit award covering 100,000 shares of common stock. The award recognizes his continued leadership of the company’s product development efforts for the treatment of atrial fibrillation.

The RSUs vest in full on the third anniversary of the grant date, subject to the terms of the grant agreement and the company’s Amended and Restated 2017 Equity Incentive Plan. This is an equity-based compensation grant designed to align the CTO’s incentives with long-term company performance.

Pulse Biosciences filed an 8-K describing a strategic and organizational realignment to prioritize development and future commercialization of its nPulse Cardiac Catheter Ablation System for treating atrial fibrillation. The company is reallocating capital and resources toward its electrophysiology program after reporting strong feasibility data.

In the near term, the realignment includes reducing headcount in sales and marketing while actively hiring in product development roles. The move follows European feasibility results in over 150 patients that the company describes as demonstrating speed, safety, and durable efficacy, with additional 12‑month follow-up data to be presented at Heart Rhythm 2026.

Pulse Biosciences, Inc. filed an 8-K after announcing first patient enrollments in a multi-center, first-in-human feasibility study of its nPulse Vybrance Percutaneous Electrode System for treating T1N0M0 papillary thyroid microcarcinoma, a common low-risk thyroid cancer. Initial procedures were successfully completed at Sarasota Memorial Health Care System in Florida and The University of Texas MD Anderson Cancer Center in Texas.

The study plans to enroll 30 patients with tumors under 1.5 cm to evaluate the safety and effectiveness of the Vybrance System, which uses Nanosecond Pulsed Field Ablation (nsPFA) to nonthermally remove cellular tissue while sparing surrounding structures. The system already holds FDA 510(k) clearance for soft tissue ablation and is now being evaluated under an Investigational Device Exemption specifically for thyroid cancer, with the study funded in part by the company.

Pulse Biosciences filed an 8-K to share new long-term clinical data from its nPulse Vybrance Percutaneous Electrode System first-in-human feasibility study for benign thyroid nodules using nsPFA energy. The extension study followed 21 patients for 15–22 months to assess durability of treatment effects.

The company reports an average 74% volume reduction in treated benign thyroid nodules, with no nodule regrowth observed during follow-up and no serious adverse events. Patient-reported outcomes were very strong: 100% of patients were highly satisfied with cosmetic results and 95% were highly satisfied overall at final follow-up, supporting the potential durability and tolerability of this nonthermal ablation approach.

Pulse Biosciences, Inc. furnished an updated investor presentation dated March 2026, which has been posted on its website and attached as Exhibit 99.1. The deck includes summary financial information, details on the next-generation nPulse cardiac catheter under development, and an increased focus on EP cardio ablation products and clinical development following what it describes as unprecedented clinical outcomes data from its EU feasibility study.

The company plans to use this investor presentation, in whole or in part and potentially with modifications, in meetings with investors, analysts, and others. The information is provided under a Reg FD disclosure, is considered "furnished" rather than "filed," and includes forward-looking statements that are subject to risks and uncertainties referenced in the company’s SEC filings.

Pulse Biosciences, Inc. filed an amended current report to update a prior disclosure about a leadership change. The amendment notes that on February 27, 2026, Chief Commercial Officer Kevin P. Danahy notified the company that he was resigning, effective immediately. The amended report states it was filed to remove two sentences from the original filing, but does not change the core fact of his immediate departure. The company continues to be led by President and Chief Executive Officer Paul A. LaViolette, who signed the report.

Pulse Biosciences, Inc. reported that its Chief Commercial Officer, Kevin P. Danahy, resigned from the company effective immediately on February 27, 2026. The company stated that his resignation was not due to any disagreement regarding operations, policies, practices, or accounting matters.

The filing notes that Mr. Danahy played an important role in senior management and in the company’s early commercialization efforts, and extends well wishes for his future endeavors.

Pulse Biosciences, Inc. reported early commercial revenue and higher operating losses as it advances its nPulse nanosecond PFA platform. Fourth quarter 2025 revenue was $264 thousand, up from $86 thousand in the prior quarter, and full-year 2025 revenue reached $350 thousand.

GAAP costs and expenses for 2025 were $77.3 million, up from $56.3 million, driving a GAAP net loss of $72.8 million versus $53.6 million a year earlier. Non-GAAP net loss rose to $50.8 million from $36.9 million. Cash and cash equivalents were $80.7 million as of December 31, 2025, down from $118.0 million a year earlier.

The company highlighted strong feasibility data in atrial fibrillation, with 100% procedural success at six months and 96% at one year in evaluable patients treated with the nPulse Cardiac Catheter System. It received FDA approval to commence a pivotal IDE study in paroxysmal AF, is running the NANOCLAMP AF surgical IDE pivotal study, and is expanding soft tissue ablation efforts, including a collaboration with MD Anderson for thyroid tumors.

Pulse Biosciences, Inc. entered into a new equity distribution agreement with TD Securities (USA) LLC, allowing the company to sell, from time to time, shares of common stock with an aggregate offering price of up to $59,976,196 in at-the-market transactions. TD Cowen will act as sales agent and receive a commission of up to 3.0% of the gross sales price of shares sold, plus specified expense reimbursements. The shares will be issued under existing effective shelf registration statements and a prospectus supplement filed on February 19, 2026. On February 18, 2026, the company terminated its prior at-the-market program, under which the same aggregate amount of common stock remained unsold.

Pulse Biosciences, Inc. reported new 6- and 12‑month results from its first‑in‑human feasibility study of the nPulse Cardiac Catheter System for treating atrial fibrillation. In an initial cohort of 150 patients, procedural success was 100% in 75 evaluable patients at 6 months and 96% in 47 evaluable patients at 12 months.

Across 150 treated patients, serious adverse events related to the primary safety endpoint occurred in 1.3% of subjects (2/150). Procedures used an average of 16.1 ± 5.2 applications, with total procedure and fluoroscopy times of 65 ± 28 and 9.8 ± 5.8 minutes, and left atrial dwell time of 21.0 ± 13.3 minutes.

Pulse Biosciences, Inc. furnished a current report describing that on January 14, 2026 it posted an updated investor presentation on its website. The updated deck highlights recent progress in product development programs for its proprietary nPulse Vybrance Percutaneous Electrode, nPulse Cardiac Clamp and nPulse Cardiac Catheter. The company plans to use this presentation in meetings with investors, analysts and others, and has attached it as Exhibit 99.1 and made it available in the Investors section of its website. The information is provided under a Regulation FD disclosure item and is treated as “furnished,” not “filed,” which limits certain legal liabilities.

Pulse Biosciences, Inc. reported that its Board of Directors elected Maria Sainz as a director, effective immediately, and appointed her to the Audit Committee. She will serve until the 2026 annual meeting of stockholders, subject to earlier departure events. Sainz is currently President and Chief Executive Officer of Hyperfine, Inc. and brings over 30 years of healthtech operating experience, including prior CEO roles at AEGEA Medical, CardioKinetix, and Concentric Medical, and board roles at several listed medical technology companies.

Under the company’s non-employee director compensation policy, Sainz is entitled to an annual cash retainer of $55,000 for Board service and $13,000 for Audit Committee service, paid quarterly, with the option to convert some or all of these retainers into stock options. She received an initial option to purchase 50,000 shares of common stock, vesting over three years, and will be eligible for annual options to purchase 30,000 shares at each future annual meeting, vesting over one year, while she remains a director. The company also noted there are no family relationships or related party transactions involving Sainz and disclosed a press release announcing her appointment.

Pulse Biosciences, Inc. reported that the U.S. Food and Drug Administration has approved its Investigational Device Exemption submission, allowing the company to start its NANOPULSE-AF clinical study for treating paroxysmal atrial fibrillation. This single-arm, multicenter, prospective trial will evaluate the primary safety and effectiveness of the company’s nPulse Cardiac Catheter System in patients with recurrent, drug‑resistant, symptomatic paroxysmal atrial fibrillation.

The study is planned to enroll up to 145 patients across as many as 30 sites, including three sites outside the United States. Pulse Biosciences disclosed this update through a press release that is filed as an exhibit and incorporated by reference.

Pulse Biosciences (PLSE) furnished an updated investor presentation as Exhibit 99.1. The deck highlights recent progress across its nPulse Vybrance Percutaneous Electrode, nPulse Cardiac Clamp, and nPulse Cardiac Catheter programs. The company may use the materials in meetings with investors and analysts.

The presentation is available on the company’s website and is treated as “furnished” under Item 7.01, not “filed,” which limits associated Exchange Act liabilities. It contains forward‑looking statements and reflects information as of November 2025.

Pulse Biosciences (PLSE) furnished an 8-K announcing it issued a press release with financial and operational results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference. The company states this information is being furnished and shall not be deemed filed under the Exchange Act.

The filing reiterates the company’s common stock trades on Nasdaq under the symbol PLSE. The press release, dated November 5, 2025, provides the detailed business update and quarterly results referenced in this report.

Pulse Biosciences (PLSE) announced first patient enrollment in its NANOCLAMP AF clinical trial, a single-arm, prospective multicenter study evaluating the safety and effectiveness of the nPulse Cardiac Surgical System for treating atrial fibrillation during concomitant surgical procedures.

The company reported that the first procedure was successfully completed at St. Helena Hospital in St. Helena, California. A related press release was furnished as Exhibit 99.1. This update reflects early clinical progress for the cardiac surgical application of the company’s pulsed-field technology.

Pulse Biosciences reported late-breaking first‑in‑human feasibility results for its nPulse™ Cardiac Surgical System. The study has treated 44 patients across three investigators, with an initial cohort of 24 patients evaluated by electroanatomical mapping about ~3 months after ablation. Key clinical outcomes: posterior box isolations were acutely successful in 100% of cases in the high‑dose cohort; pulmonary vein isolation (PVI) success per vein at ~3 months was 94% (63 of 67); average total ablation time was 50 seconds with an average of 13 applications. No esophageal or phrenic nerve damage and no ablation‑related severe or major adverse events were reported. The company attached a press release as Exhibit 99.1 describing presentation of these results at the European Association for Cardio‑Thoracic Surgery annual meeting.

PULSE BIOSCIENCES reported director compensation and a leadership update. The company's board ratified awards granted August 9, 2024, comprising three grants of 200,000 option shares each for a total of 600,000 options. The filing notes 2,753,901 broker non-votes on an item reported as "Against" and includes an entry of "N/A" for related fields. It also states that Mr. LaViolette became President and Chief Executive Officer on January 9, 2025 and remains an ex officio member of the Strategic Advisory Committee.

Pulse Biosciences announced FDA approval of an Investigational Device Exemption (IDE) to begin a clinical study of its nsPFA Cardiac Surgical System for treating atrial fibrillation (AF). The approved NANOCLAMP AF study is a single-arm, prospective trial designed to show primary effectiveness when used in concomitant cardiac surgery. Up to 20 sites (including two outside the U.S.) are planned to enroll as many as 136 patients. The filing attaches a company press release and reiterates standard forward-looking statement cautions about clinical, regulatory, and technological risks.

Pulse Biosciences announced the enrollment of the first patients in a multicenter, IRB-approved study (PRECISE) evaluating its nsPFA™ Percutaneous Electrode System to treat benign thyroid nodules (BTNs). The filing states the press release dated September 2, 2025, confirms successful initial procedures and that the release is attached as Exhibit 99.1.

The company describes the study as multicenter and IRB-approved, indicating clinical development progress for its proprietary nsPFA technology in a new indication. No financial results, timelines for completion, patient numbers beyond “first patients,” or efficacy/safety data are included in the filing.

Pulse Biosciences announced publication of early clinical data from a first-in-human, single-arm feasibility study of its CellFX nsPFA Percutaneous Electrode System to treat benign thyroid nodules. The study, conducted at a single center in Naples, Italy, used ultrasound-guided ablation for tissue-response assessments and therapeutic intent. Follow-up ultrasounds showed no intranodular fibrosis or scarring. Fully treated nodules had an average 86% reduction in size at one year, with individual reductions up to 93%, and patients experienced symptom relief with reductions greater than 48% as early as two weeks. The company attached the related press release as an exhibit.

Pulse Biosciences, Inc. furnished a Form 8-K to report that it announced financial and operational results for the fiscal quarter ended June 30, 2025. The company stated that a press release containing those results is attached as Exhibit 99.1 and is incorporated by reference. The filing clarifies that the information and the exhibit are being furnished and are not to be deemed "filed" under the Exchange Act for purposes of Section 18, nor incorporated by reference in other filings except by specific reference. No numerical financial metrics or narrative detail from the press release are included in this Form 8-K.

Pulse Biosciences, Inc. (Nasdaq: PLSE) filed a Form 8-K announcing the appointment of Steven T. Weber as Vice President of Accounting & Global Corporate Controller, effective 14 Jul 2025. Weber will also assume the role of principal accounting officer, succeeding the prior incumbent (not specified in the filing). The 25-year finance veteran most recently served as SVP, Corporate Controller & PAO at IGM Biosciences and previously held senior roles at Aeglea Biotherapeutics and PwC.

Compensation & equity incentives: Weber’s cash compensation (base salary and target bonus) aligns with existing VP pay bands; specific dollar amounts were not disclosed. He received a non-statutory option for 55,000 shares at an exercise price of $16.03 (close of 11 Jul 2025). Vesting structure:

• Time-based: 27,500 shares vest 25% on the 1-year anniversary then quarterly over three additional years.
• Performance-based: up to 27,500 shares vest in four equal tranches tied to market-cap milestones of $1.5 B, $2.25 B, $3.0 B, and $4.0 B, each requiring 270 consecutive days and no earlier than year-end 2026-2029.

Weber signed standard inventions, confidentiality, non-competition and indemnification agreements. There are no related-party transactions or family relationships disclosed.

Investor takeaways: This is a governance-focused event that strengthens the finance function with a seasoned CPA. The equity package is modest (~0.2% of shares outstanding) and heavily performance-weighted, aligning Weber’s incentives with long-term shareholder value. No immediate financial impact or guidance changes were provided.